Eric Halioua

President & Chief Executive Officer • PDC*Line Pharma

Eric Halioua is a serial entrepreneur that combines strong strategic, technological and managerial experience with a proven track record of deal-making and fund-raising. During his career, he achieved together with his different teams to bring four drug candidates from research to the clinics (up to phase IIb). As of now, Eric has raised over €160 million from VCs and strategic partners in Europe, the USA, Japan and Korea and has had numerous successes in the sale and initial public offering of biotechnology companies. He is the CEO of the biotechnology company PDC*line Pharma andboard member of Essenscia (Bio.be). Eric is co-founder of four biotechnology companies called Myosix (bought by Genzyme mid-2002), Murigenetics, HairClone and Digital Orthopaedics. He is the co-inventor of the first GMP-approved mobile manufacturing unit for cell therapy. Eric worked for 12 years in the Healthcare and Life Sciences Practice of Arthur D. LittleEric holds two master’s degrees in pharmacology and Molecular Biology and an MBA from ESSEC business school (Paris, France), with an advanced degree from the Health Care ESSEC chair. 

Also speaking

Ben Weil

Director of Manufacturing  • INmune Bio

Jenny Stjernberg

PhD, Director, Commercial Operations EMEA • ScaleReady

Niloofar Davoodi

Product Operations Lead, Cell Therapy • Takeda

Event Info


Innovation Zone

Find out more about the Innovation Zone at Advanced Therapies Europe.

Advanced Therapies Investment Summit

Find out more about the Investor Pre-Day taking place 10th September 2024.